Subscribe To

Price Alert Latest News Economic Calendar News

BRAXF / Braxia Scientific reports promising preliminary results from Phase 2 of its psilocybin-assisted therapy trial for treatment-resistant depression

Braxia Scientific reports promising preliminary results from Phase 2 of its psilocybin-assisted therapy trial for treatment-resistant depression

Braxia Scientific Corp announced that preliminary results from a Phase 2 clinical trial of multi-dose psilocybin-assisted therapy for treatment-resistant depression showed clinically meaningful movements in depression severity. Braxia Scientific's ongoing multi-dose psilocybin trial effectively demonstrated the feasibility of its proprietary psilocybin-assisted therapy protocol with high rates of recruitment and retention with adequate tolerability and safety, the company said. Read More

Demo Live Account See Partner Details

Content Topics

Braxia

Scientific

Reports

Promising

Preliminary

Results

From

Psilocybin assisted

Therapy

Treatment resistant

Depression

Stock

BRAXF

Posted: Jun 2 2022, 09:35

Author Name: Proactive Investors

BRAXF News

By Proactive Investors
June 9, 2023

Braxia Scientific reports significant increase in treatment volumes across its clinics

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has reported a significant increase in treatment volumes across its clinics, which rose by 26.2% in fi

By Proactive Investors
February 28, 2023

Braxia Scientific closes first tranche of its non-brokered offering for aggregate proceeds of $751,218.83

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) said it has closed the first tranche of its previously announced non-brokered offering resulting in the

By Proactive Investors
February 7, 2023

Braxia Scientific announces up to $1.5M offering and concurrent private placement

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has announced an offering of up to 27,272,727 units of the company at a price of $0.055 each for aggrega

By Proactive Investors
November 30, 2022

Braxia Scientific sees Q2 revenue increase, with in-clinic treatment up 34.5%

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has announced an increase in revenues for its second quarter and the first half ended September 30, 202

By Proactive Investors
August 30, 2022

Braxia Scientific reports 13% rise in Q1 revenue; launches KetaMD in US

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) (Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF), Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF)) has annou

By Proactive Investors
August 1, 2022

Braxia Scientific lifts revenue and narrows loss in fiscal 2022 as it looks to "significantly" scale offerings

Braxia Scientific Corp has reported a near 50% increase in revenue in its fiscal year to end-March 2022 as it looks to "significantly" scale its offe

By Proactive Investors
July 27, 2022

Braxia Scientific appoints tech industry veteran Jason Wolkove as its CIO, Daniel Herrera as VP of R&D

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has announced the appointments of Jason Wolkove as the company's new chief information officer (CIO) as

By Proactive Investors
June 15, 2022

Braxia Scientific expands Canadian mental health clinic footprint with newest location in Ontario's Kitchener-Waterloo region

Braxia Scientific Corp has announced the opening of its newest Braxia Health clinic in the Kitchener-Waterloo area in Ontario, its fifth locatio

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.